Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19
Résumé
Background:A subset of patients with coronavirus dis-ease 2019 (COVID-19) will develop acute respiratory distresssyndrome and require mechanical ventilation. Studies sug-gest that many patients with COVID-19 and acute respiratorydistress syndrome experience a cytokine storm characterizedby fever; hyperferritinemia; and a massive release of inflam-matory cytokines, including interleukin-6, tumor necrosisfactor-, and monocyte chemoattractant proteins (1). Thesefindings led to the hypothesis that biological agents targetingspecific cytokine or inflammatory pathways may improve therespiratory outcomes of patients with the most severe formsof COVID-19 (2)